Welcome! You are visiting the MyeloRx web site.

Home
About Us
Contact Us
Site Map
Lead Compounds
Clinical Efficacy - Leuke
Natural Products
Our Strategy
Intellectual Property
Targets
Acute Myeloid Leukemia
Lead Compound - MRx102
MRx102
AML Xenograft Model (MV4-
Pilot Toxicity
Summary
Clinical Efficacy - Leukemia
 
Evaluated by a Medical Sciences Institute
 
Used I.V. dose of 30 µg/kg/day
 
45 leukemia patients treated
18 complete responses (40%)
 
6 partial responses (13%)
 
Side effects include phlebitis at injection site and gastrointestinal